Generics and Biologics: Driving the Future of the MENA Pharmaceutical Market
Generics are pharmaceutical equivalents of branded drugs, identical in dosage, strength, and intended use, but offered at a fraction of the cost once original patents expire. They play a crucial role in reducing healthcare expenses and improving accessibility across all socioeconomic groups. Conversely, biologics—complex therapies derived from living organisms—are designed to target specific, often severe diseases such as cancer and autoimmune disorders. With technological advancements, biosimilars—cost-effective, near-identical versions of biologics—are rapidly gaining prominence worldwide, including across the MENA region.
The demand for both generics and biologics is expanding in the MENA region due to population growth and the rising prevalence of chronic diseases. Governments and healthcare providers are striving to balance affordability with access to innovative therapies, reflecting a dual commitment: generics for widespread, cost-effective treatment and biologics for tackling complex, life-threatening conditions.
The MENA pharmaceutical market is witnessing dynamic growth, fueled by healthcare reforms, increasing medical needs, and technological progress in drug manufacturing. Generics are becoming integral to national healthcare strategies, with nations such as Saudi Arabia and the UAE prioritizing domestic production to enhance drug availability and reduce import dependence. Under Vision 2030, Saudi Arabia is actively expanding its pharmaceutical industry through policies that encourage generic procurement and clinical trials. Iran, meanwhile, stands out for its well-established generic drug manufacturing base, effectively meeting local demand. Countries like Jordan and Algeria are also promoting generics to reconcile healthcare affordability with rising demand, with Jordan recognized for producing high-quality yet affordable generics.
Biologics and biosimilars are emerging as high-growth categories across the region. Between 2015 and 2019, the MENA biologics market reached a value of USD 4.1 billion, growing at an annual rate of 14.5%. Saudi Arabia leads the segment, contributing over USD 1.8 billion, followed by Egypt, the UAE, and Algeria. Biosimilars are expected to grow at a CAGR of 24.96% (2021–2026), driven by increasing healthcare expenditures and the need for advanced therapies. Together, these developments underscore the region’s ambition to become a hub for affordable yet innovative pharmaceutical solutions.
The regulatory environment across the MENA region combines international standards with localized policies. Due to their complexity, biologics undergo rigorous approval procedures involving clinical, analytical, and pharmacovigilance evaluations. Agencies such as the Saudi Food and Drug Authority (SFDA) model their frameworks on the FDA and EMA, with regional adaptations—for instance, incorporating GCC-specific guidelines to facilitate biologic approvals. However, inconsistent pathways among MENA countries often slow biosimilar adoption and impede regional harmonization.
For generics, most countries are moving toward localization to reduce import dependence and improve access. The UAE and Jordan have relatively efficient generic approval systems, while others still face bureaucratic delays. Ongoing reforms around pricing, clinical trials, and registration present both challenges and opportunities. Streamlined, region-wide cooperation could accelerate drug approvals, enhance public confidence, and improve overall healthcare outcomes.
Generic drug manufacturing is rapidly expanding across the MENA region, supported by rising healthcare demand, government policies, and a strong push for local production. Countries like Saudi Arabia and the UAE are actively investing in domestic manufacturing to control healthcare costs and strengthen their pharmaceutical industries. Partnerships between international firms and local manufacturers are driving new facilities, joint ventures, and R&D investments.
The UAE, for example, has seen its number of pharmaceutical factories grow from 4 in 2010 to 23 in 2022, with more expected in the coming years. Growth is being driven by the need for affordable oncology treatments, increasing biosimilar approvals, and expanding government healthcare investments. Technological advances such as automation and improved quality systems have enhanced manufacturing efficiency.
Notably, Mubadala Investment Company’s acquisition of KELIX Bio in 2024 reflects the UAE’s ambitions to establish a regional biopharmaceutical hub. Meanwhile, GCC nations continue focusing on branded and specialty generics, while African counterparts emphasize high-volume, low-cost production, together ensuring broader access to essential medicines.
Biologics and biosimilars are gaining momentum in the MENA region as government reforms and healthcare modernization accelerate adoption. Biologics are indispensable for managing complex diseases, while biosimilars provide a more cost-effective alternative.
Under Saudi Vision 2030, Saudi Arabia is investing heavily in local biopharmaceutical R&D and international partnerships. The UAE is positioning itself as a biopharma innovation hub, with initiatives like Mubadala’s biosimilar production ventures. Egypt is enhancing regulatory oversight and pharmacovigilance to ensure biosimilar safety and efficacy.
Despite progress, challenges persist—chiefly fragmented regulations, limited manufacturing infrastructure, and reliance on imports. Nonetheless, public-private collaborations, coupled with alignment to global standards (EMA, FDA), are steadily shaping a more resilient and accessible biopharmaceutical ecosystem across MENA.
Generics and biosimilars play a vital role in reducing healthcare costs and improving medicine accessibility. Governments across MENA are prioritizing policies that encourage their adoption. For instance, Egypt’s Ministry of Health has promoted generic use, lowering drug prices and increasing availability.
Similarly, Saudi Arabia’s SFDA has developed comprehensive biosimilar guidelines to ensure high safety and efficacy standards while fostering competition. The Pharmacy and Therapeutics Committees (PTCs) across GCC nations evaluate drugs for cost-effectiveness, ethics, and safety, setting robust guidelines for biosimilar prescribing and reimbursement.
The UAE’s National Strategy for Pharmaceuticals aims to locally produce 50% of its medicines by 2030, including both generics and biosimilars. Regional cooperation and regulatory harmonization are also gaining traction to facilitate cross-border access and market integration.
Strategic collaborations are driving the expansion of generics and biosimilars in the MENA region:
Public-Private Partnerships (Oman): Encouraging local biosimilar production and export capacity.
Hikma Pharmaceuticals & Celltrion: Enhancing biosimilar access and physician awareness across MENA.
Biocon & Tabuk Pharmaceuticals (2024): Licensing agreement to commercialize GLP-1 products for diabetes and weight management, aligning with Saudi Vision 2030.
WHO Guidelines Adoption: Egypt has led the adoption of updated biosimilar approval standards, paving the way for broader regional acceptance.
India’s Export Role: As MENA’s largest supplier of generics and biosimilars, India strengthens accessibility and cost-effectiveness through trade and joint manufacturing.
Regional Collaboration: The 2nd MENA Stakeholder Meeting on Biosimilars underscored the importance of harmonized frameworks and shared best practices.
Saudi Arabia: Through its National Biotechnology Strategy and Vision 2030, the Kingdom aims to become a biotechnology leader, offering incentives for local biopharma manufacturing and self-sufficiency.
United Arab Emirates: The Emirati Genome Programme and fast-track biosimilar approval systems are positioning the UAE as a center for personalized medicine and biopharmaceutical innovation.
Egypt: With the Egyptian Drug Authority’s updated biosimilar regulations and strong post-marketing surveillance, Egypt is emerging as a regional hub for biosimilar development.
Jordan and Tunisia: Both countries maintain EMA-aligned regulatory systems that support generic and biologic growth, encouraging local investment and boosting healthcare accessibility.
The future of the MENA pharmaceutical industry is marked by innovation, collaboration, and strategic reform. With strong policy support from Saudi Arabia, the UAE, and Egypt, the region is building a balanced ecosystem that combines affordability with innovation.
Challenges such as regulatory fragmentation, limited large-scale production capabilities, and dependence on imports persist. Addressing these issues through regional harmonization, R&D investment, and public-private collaboration will be key.
Agencies like the SFDA, MOHAP, and EDA, alongside the GCC Health Council, are central to ensuring unified policies and high safety standards. With sustained commitment, the MENA region is well-positioned to become a global pharmaceutical hub, delivering affordable, high-quality, and innovative healthcare solutions for all.